Investor Resources Home

At Heron, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents.
HRTX (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$18.18
Change (%) Stock is Down 0.22 (1.20%)
Volume638,059
Data as of 09/23/16 4:00 p.m. ET
Refresh quote

Corporate Presentation

DateTitle
09/14/16
Download Documentation Corporate Presentation – September 2016

Recent News

More >>
DateTitle 
09/08/16Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016Printer Friendly Version
08/29/16Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek® 2016Printer Friendly Version
08/10/16Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and VomitingPrinter Friendly Version
08/08/16Heron Therapeutics Reports Second Quarter 2016 Financial Results and Recent Corporate ProgressPrinter Friendly Version

Upcoming Events

More >>

There are currently no events scheduled.

Data provided by NASDAQ. Minimum 15 minutes delayed.